Literature DB >> 10520731

Interspecies variability and drug interactions of clozapine metabolism by microsomes.

H Bun1, B Disdier, C Aubert, J Catalin.   

Abstract

Cytochrome P450 expression in liver is influenced by several factors, including species, sex and strain. We compared metabolism formation of clozapine in different species (rat, mouse, guinea-pig, dog, monkey and man) so as to choose between species to further validate interaction studies. Liver microsomes of male and female Sprague-Dawley rats, hairless rats, OF1 mice, Balb C mice and Dunkin-Hartley albino guinea-pigs, male beagle dogs, male cynomolgus monkeys and man were used to investigate in vitro metabolism of clozapine. This process was dependent on the presence of NADPH and on the presence of microsome protein. In addition, we observed the formation of desmethyl- and N-oxide metabolites, with the rate of formation of each of these compounds varying with species, sex and strain of microsomes incubated. The desmethyl- and N-oxide metabolites formed were statistically greater in male than in female rats, mice in the two strains studied, as well as for the guinea-pigs. Levels of desmethyl clozapine formed were high for the rats and no significant difference in clozapine biotransformation was observed between Sprague-Dawley and hairless rats. For man, the formation of metabolites of clozapine was comparable with guinea-pig, dog and monkey. In addition, we screened the effect of 52 molecules, representative of 11 different therapeutic classes, on the metabolism of clozapine by rat liver microsomes. We found that most of the calcium channel blockers (diltiazem, felodipine, isradipine, lacidipine, nicardipine and nitrendipine), antifungals (ketoconazole, miconazole) and two anticancer drugs (paclitaxel, teniposide) caused more than 50% inhibition of clozapine metabolism in vitro. The extent of inhibition was increased in a concentration-dependant manner. Complementary clinical and pharmacokinetic studies should be performed to confirm these results.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10520731     DOI: 10.1111/j.1472-8206.1999.tb00364.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  8 in total

1.  CNO Evil? Considerations for the Use of DREADDs in Behavioral Neuroscience.

Authors:  Stephen V Mahler; Gary Aston-Jones
Journal:  Neuropsychopharmacology       Date:  2018-02-07       Impact factor: 7.853

2.  AMPA receptor subunit and splice variant expression in the DLPFC of schizophrenic subjects and rhesus monkeys chronically administered antipsychotic drugs.

Authors:  J A O'Connor; E C Muly; S E Arnold; S E Hemby
Journal:  Schizophr Res       Date:  2006-12-01       Impact factor: 4.939

3.  YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice.

Authors:  Rui Song; Ri-Fang Yang; Ning Wu; Rui-Bin Su; Jin Li; Xiao-Qing Peng; Xia Li; József Gaál; Zheng-Xiong Xi; Eliot L Gardner
Journal:  Addict Biol       Date:  2011-04-20       Impact factor: 4.280

4.  Further characterization of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in C57BL/6 mice: role of 5-HT(2A) serotonergic and alpha (1) adrenergic antagonism.

Authors:  Scott D Philibin; D Matthew Walentiny; Sarah A Vunck; Adam J Prus; Herbert Y Meltzer; Joseph H Porter
Journal:  Psychopharmacology (Berl)       Date:  2008-11-07       Impact factor: 4.530

5.  Clozapine toxicity due to a multiple drug interaction: a case report.

Authors:  Giovanna Cadeddu; Arianna Deidda; Maria Erminia Stochino; Nicola Velluti; Caterina Burrai; Maria Del Zompo
Journal:  J Med Case Rep       Date:  2015-04-02

6.  The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice.

Authors:  Daniel F Manvich; Kevin A Webster; Stephanie L Foster; Martilias S Farrell; James C Ritchie; Joseph H Porter; David Weinshenker
Journal:  Sci Rep       Date:  2018-03-01       Impact factor: 4.379

7.  Enhanced disease reduction using clozapine, an atypical antipsychotic agent, and glatiramer acetate combination therapy in experimental autoimmune encephalomyelitis.

Authors:  Laura K Green; Pirooz Zareie; Nikki Templeton; Robert A Keyzers; Bronwen Connor; Anne Camille La Flamme
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-03-17

8.  Clozapine N-Oxide Administration Produces Behavioral Effects in Long-Evans Rats: Implications for Designing DREADD Experiments.

Authors:  Duncan A A MacLaren; Richard W Browne; Jessica K Shaw; Sandhya Krishnan Radhakrishnan; Prachi Khare; Rodrigo A España; Stewart D Clark
Journal:  eNeuro       Date:  2016-11-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.